All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

delorazepam 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
diazepam derivatives	800	2894-67-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: delorazepam chlordemethyldiazepam chlordesmethyldiazepam chlorodesmethyldiazepam	Molecular weight: 305.16 Formula: C15H10Cl2N2O CLOGP: 3.08 LIPINSKI: 0 HAC: 3 HDO: 1 TPSA: 41.46 ALOGS: -4.68 ROTB: 1

Drug dosage:

None

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.28 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	2.20 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.17 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.05 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	200 hours	Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	3.007		High	0.81
caco2-efflux	Caco-2 efflux ratio (BA/AB)	0.403		High	0.81
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	90.157	10^-6 cm/s	High	0.81
dh-clint	Dog hepatocyte intrinsic clearance	15.241	uL/min/10^6 cells	High	0.81
dppb	Dog plasma protein binding (% unbound)	6.350	%	High	0.81
fcs-ppb	Fetal calf serum protein binding (% unbound)	16.070	%	High	0.81
herg	hERG pIC50	4.497	pIC50	High	0.81
hh-clint	Human hepatocyte intrinsic clearance	1.365	uL/min/10^6 cells	High	0.81
hlm-clint	Human liver microsomal intrinsic clearance	4.699	uL/min/mg protein	High	0.81
hppb	Human plasma protein binding (% unbound)	7.470	%	High	0.81
kinase-safety-class	EIF2AK3,PDK1,PDK2,PDK4	4
kinase-selectivity-class	GRK2	1
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	1.122		High	0.81
mh-clint	Mouse hepatocyte intrinsic clearance	31.189		High	0.81
mppb	Mouse plasma protein binding (% unbound)	9.320		High	0.81
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	2.500		High	0.81
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	11	%	High	0.81
rh-clint	Rat hepatocyte intrinsic clearance	28.973	uL/min/10^6 cells	High	0.81
rh-fuinc	Rat hepatocyte fraction unbound in incubation	53.330	%	High	0.81
rppb	Rat plasma protein binding (% unbound)	7.840	%	High	0.81
solubility-dd	Solubility at pH 7.4 in DMSO	30.761	uM	High	0.81

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug abuse	1983.96	59.28	502	3683	81845	90542417
Sopor	1906.18	59.28	390	3795	24254	90600008
Intentional self-injury	995.12	59.28	237	3948	29097	90595165
Intentional overdose	235.26	59.28	105	4080	93729	90530533
Suicide attempt	184.46	59.28	83	4102	75316	90548946
Bradyphrenia	154.67	59.28	41	4144	7571	90616691
Poisoning	143.12	59.28	45	4140	15172	90609090
Toxicity to various agents	141.18	59.28	112	4073	287734	90336528
Substance abuse	109.25	59.28	29	4156	5377	90618885
Intentional product misuse	96.98	59.28	57	4128	89547	90534715
Coma	96.94	59.28	53	4132	72579	90551683
Psychomotor hyperactivity	96.41	59.28	32	4153	12781	90611481
Somnolence	90.99	59.28	76	4109	209008	90415254
Overdose	80.59	59.28	63	4122	157646	90466616
Sluggishness	79.13	59.28	23	4162	5936	90618326
Hypotension	69.31	59.28	80	4105	325317	90298945
Tachycardia	65.81	59.28	56	4129	157617	90466645
Bradykinesia	63.48	59.28	20	4165	6768	90617494

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sopor	977.88	54.37	207	2087	12995	42606046
Drug abuse	531.52	54.37	201	2093	104570	42514471
Intentional self-injury	326.16	54.37	88	2206	15114	42603927
Toxicity to various agents	106.62	54.37	92	2202	229044	42389997
Bradyphrenia	101.08	54.37	28	2266	5234	42613807
Respiratory depression	79.64	54.37	32	2262	18836	42600205
Drug interaction	69.21	54.37	78	2216	266921	42352120
Bradykinesia	60.67	54.37	19	2275	5417	42613624
Overdose	58.48	54.37	47	2247	105217	42513824
Psychomotor hyperactivity	58.31	54.37	22	2272	10936	42608105
Intentional overdose	56.78	54.37	35	2259	51421	42567620

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sopor	2757.34	54.09	590	5862	35956	110546891
Drug abuse	2233.76	54.09	685	5767	176726	110406121
Intentional self-injury	1296.17	54.09	322	6130	37107	110545740
Intentional overdose	257.24	54.09	134	6318	132367	110450480
Bradyphrenia	245.77	54.09	68	6384	11660	110571187
Toxicity to various agents	231.33	54.09	204	6248	480351	110102496
Suicide attempt	201.77	54.09	105	6347	103289	110479558
Psychomotor hyperactivity	149.91	54.09	53	6399	20224	110562623
Coma	133.57	54.09	84	6368	117785	110465062
Overdose	117.47	54.09	102	6350	233692	110349155
Poisoning	110.93	54.09	47	6405	29058	110553789
Bradykinesia	110.40	54.09	36	6416	10752	110572095
Somnolence	107.45	54.09	108	6344	297341	110285506
Sluggishness	101.31	54.09	31	6421	7536	110575311
Intentional product misuse	101.03	54.09	74	6378	132830	110450017
Substance abuse	93.71	54.09	33	6419	12430	110570417
Sedation	79.70	54.09	50	6402	69633	110513214
Drug interaction	79.50	54.09	120	6332	500063	110082784
Confusional state	72.41	54.09	111	6341	468569	110114278
Confabulation	65.80	54.09	13	6439	508	110582339
Respiratory depression	60.86	54.09	32	6420	31969	110550878
Tachycardia	60.13	54.09	70	6382	226575	110356272
Psychomotor retardation	59.98	54.09	21	6431	7771	110575076
Serotonin syndrome	54.31	54.09	37	6415	59116	110523731
Aggression	54.28	54.09	37	6415	59173	110523674

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
MeSH PA	D000927	Anticonvulsants
MeSH PA	D002491	Central Nervous System Agents
CHEBI has role	CHEBI:35474	anti-anxiety agents
CHEBI has role	CHEBI:35623	anticonvulsants
CHEBI has role	CHEBI:35717	hypnotics
CHEBI has role	CHEBI:50268	GABA modulators
CHEBI has role	CHEBI:77746	Homo sapiens metabolite

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.52	acidic
pKa2	2.23	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
GABA-A receptor alpha-1/beta-2/gamma-2	Ion channel	P14867 P18507 P47870	GBRA1_HUMAN GBRG2_HUMAN GBRB2_HUMAN		IC50	8.75		WOMBAT-PK
GABA-A receptor; anion channel	Ion channel	O00591 O14764 P14867 P18505 P18507 P28472 P31644 P34903 P47869 P47870 P48169 P78334 Q16445 Q8N1C3 Q99928 Q9UN88	GBRP_HUMAN GBRD_HUMAN GBRA1_HUMAN GBRB1_HUMAN GBRG2_HUMAN GBRB3_HUMAN GBRA5_HUMAN GBRA3_HUMAN GBRA2_HUMAN GBRB2_HUMAN GBRA4_HUMAN GBRE_HUMAN GBRA6_HUMAN GBRG1_HUMAN GBRG3_HUMAN GBRT_HUMAN		IC50	8.55		CHEMBL

External reference:

ID	Source
D07784	KEGG_DRUG
C0055353	UMLSCUI
CHEBI:135295	CHEBI
CHEMBL268254	ChEMBL_ID
DB01511	DRUGBANK_ID
17925	PUBCHEM_CID
4510	INN_ID
O91W32476G	UNII
1351681008	SNOMEDCT_US
C013434	MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

None